These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 29061751

  • 21. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers.
    Cass LM, Efthymiopoulos C, Bye A.
    Clin Pharmacokinet; 1999; 36 Suppl 1():1-11. PubMed ID: 10429835
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season.
    Koseki N, Kaiho M, Kikuta H, Oba K, Togashi T, Ariga T, Ishiguro N.
    Influenza Other Respir Viruses; 2014 Mar; 8(2):151-8. PubMed ID: 23953886
    [Abstract] [Full Text] [Related]

  • 23. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate; comparison of the 2011/12 to 2015/16 Japanese influenza seasons.
    Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.
    J Infect Chemother; 2017 Sep; 23(9):627-633. PubMed ID: 28709902
    [Abstract] [Full Text] [Related]

  • 24. Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.
    Kakuta M, Kubo S, Tanaka M, Tobiume S, Tomozawa T, Yamashita M.
    Antiviral Res; 2013 Oct; 100(1):190-5. PubMed ID: 23954190
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases.
    Watanabe A.
    J Infect Chemother; 2013 Feb; 19(1):89-97. PubMed ID: 22907567
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Duration of fever and other symptoms after the inhalation of laninamivir octanoate hydrate for influenza treatment; comparison among the four Japanese influenza seasons from 2011-2012 to 2014-2015.
    Ikematsu H, Kawai N, Iwaki N, Kashiwagi S.
    J Infect Chemother; 2016 Sep; 22(9):605-10. PubMed ID: 27493024
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects.
    Shelton MJ, Lovern M, Ng-Cashin J, Jones L, Gould E, Gauvin J, Rodvold KA.
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5178-84. PubMed ID: 21896909
    [Abstract] [Full Text] [Related]

  • 37. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance.
    Kashiwagi S, Yoshida S, Yamaguchi H, Niwa S, Mitsui N, Tanigawa M, Shiosakai K, Yamanouchi N, Shiozawa T, Yamaguchi F.
    Int J Antimicrob Agents; 2012 Nov; 40(5):381-8. PubMed ID: 22871369
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Safety evaluation of laninamivir octanoate hydrate through analysis of adverse events reported during early post-marketing phase vigilance.
    Nakano T, Okumura A, Tanabe T, Niwa S, Fukushima M, Yonemochi R, Eda H, Tsutsumi H.
    Scand J Infect Dis; 2013 Jun; 45(6):469-77. PubMed ID: 23373850
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.